Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy

2005 ◽  
Vol 41 (15) ◽  
pp. 2304-2311 ◽  
Author(s):  
Youlia M. Kirova ◽  
Dominique Stoppa-Lyonnet ◽  
Alexia Savignoni ◽  
Brigitte Sigal-Zafrani ◽  
Nicolas Fabre ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contralateral Breast Cancer ◽  
Brca2 Mutation ◽  
Cancer Recurrence ◽  
Breast Conserving Surgery ◽  
Contralateral Breast ◽  
Breast Cancer Recurrence ◽  
Brca1 And Brca2 ◽  
Mutation Status

scholarly journals Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

2011 ◽  
Vol 104 (9) ◽  
pp. 1384-1392 ◽  
Author(s):  
K Metcalfe ◽  
S Gershman ◽  
H T Lynch ◽  
P Ghadirian ◽  
N Tung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contralateral Breast Cancer ◽  
Brca2 Mutation ◽  
Contralateral Breast ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

2004 ◽  
Vol 22 (12) ◽  
pp. 2328-2335 ◽  
Author(s):  
Kelly Metcalfe ◽  
Henry T. Lynch ◽  
Parviz Ghadirian ◽  
Nadine Tung ◽  
Ivo Olivotto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contralateral Breast Cancer ◽  
Brca Mutation ◽  
Brca1 Mutation ◽  
Brca2 Mutation ◽  
Contralateral Breast ◽  
Second Primary ◽  
Brca1 And Brca2 ◽  
Breast Cancer Death ◽  
Actuarial Risk

Purpose To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers after diagnosis and to determine which factors are predictive of the risk of a second primary breast cancer. Patients and Methods Patients included 491 women with stage I or stage II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up. Results The actuarial risk of contralateral breast cancer was 29.5% at 10 years. Factors that were predictive of a reduced risk were the presence of a BRCA2 mutation (v BRCA1 mutation; hazard ratio [HR], 0.73; 95% CI, 0.47 to 1.15); age 50 years or older at first diagnosis (v ≤ 49 years; HR, 0.63; 95% CI, 0.36 to 1.10); use of tamoxifen (HR, 0.59; 95% CI, 0.35 to 1.01); and history of oophorectomy (HR, 0.44; 95% CI, 0.21 to 0.91). The effect of oophorectomy was particularly strong in women first diagnosed prior to age 49 years (HR, 0.24; 95% CI, 0.07 to 0.77). For women who did not have an oophorectomy or take tamoxifen, the 10-year risk of contralateral cancer was 43.4% for BRCA1 carriers and 34.6% for BRCA2 carriers. Conclusion The risk of contralateral breast cancer in women with a BRCA mutation is approximately 40% at 10 years, and is reduced in women who take tamoxifen or who undergo an oophorectomy.

scholarly journals Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study

The Breast ◽  
2021 ◽  
Author(s):  
Delal Akdeniz ◽  
Mark van Barele ◽  
Bernadette A.M. Heemskerk-Gerritsen ◽  
Ewout W. Steyerberg ◽  
Michael Hauptmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Contralateral Breast Cancer ◽  
Brca2 Mutation ◽  
Contralateral Breast ◽  
Brca1 And Brca2 ◽  
Mutation Carriers
Sign in / Sign up

Export Citation Format

Share Document